Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication pharminent August 10, 2026
Clinical Data Intellia finds genetic suspect for liver safety signals with ATTR gene therapy pharminent August 7, 2026
M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026
News FDA Approves Moderna’s mFlusiva, the First mRNA-Based Seasonal Flu Vaccine pharminent August 6, 2026
News Eli Lilly Smashes Q2 Estimates, Raises 2026 Guidance to $85–$87B on GLP-1 Surge pharminent August 5, 2026
Pipeline Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts pharminent August 5, 2026
Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026
Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing pharminent August 5, 2026
News Pfizer Axes Ex-Metsera Obesity Asset and GIPR Prospect in Quarterly Pipeline Clearout pharminent August 4, 2026
M&A / Deals Supernus and Indivior merge to create scaled, CNS-focused entity pharminent August 4, 2026
News AstraZeneca and Bristol Myers Squibb Reported to Have Held Mega-Merger Talks pharminent August 3, 2026
M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026
News Novo Nordisk’s Ziltivekimab Misses Primary Endpoint in Pivotal Cardiovascular Trial pharminent August 1, 2026
Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026
M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026
News Amgen’s Repatha Wins Positive CHMP Opinion for Preventing First Heart Attacks and Strokes pharminent July 30, 2026
News Vertex, AbCellera Partner on Next-Generation T-Cell Engagers for Autoimmune Disease pharminent July 29, 2026
M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
News GSK Unveils Three-Year Restructuring to Fund Late-Stage R&D Ahead of Patent Cliff pharminent July 28, 2026
Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
News AstraZeneca Says Drug Pricing Is ‘Evolving’ in Response to Trump’s Most-Favored-Nation Policy pharminent July 27, 2026
M&A / Deals Argenx deepens immuno expertise with $2.2B Forte Biosciences buy pharminent July 27, 2026
News EMA CHMP Recommends Twelve New Medicines for Approval at July 2026 Meeting pharminent July 24, 2026